Quick Answer
CG Oncology, Inc. reported Earnings Per Share Diluted of $2.08 (loss) per share for the year ending 2025.
- CG Oncology, Inc. showed a decrease of -47.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from CG Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $3.22 (loss) per share | Q2 2023: $3.93 (loss) per share | Q3 2023: $4.00 (loss) per share | Q1 2024: $0.36 (loss) per share | Q2 2024: $0.28 (loss) per share | Q3 2024: $0.30 (loss) per share | Q1 2025: $0.45 (loss) per share | Q2 2025: $0.54 (loss) per share | Q3 2025: $0.57 (loss) per share.
- Over the full 3 years of available data (2023 to 2025), CG Oncology, Inc.'s Earnings Per Share Diluted has grown by 86.7%.
- Historical annual values: Fiscal year 2025: $2.08 (loss) per share | Fiscal year 2024: $1.41 (loss) per share | Fiscal year 2023: $15.65 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: